Bisphosphonate-related osteonecrosis of jaw (BRONJ): an anti-angiogenic side-effect?
1 Griffith University School of Medicine, Gold Coast Campus, Griffith University, Griffith, QLD 4222, Australia
2 Doctoral School, University of Medicine and Pharmacy Targu Mures, 38 Gh.Marinescu Street, Targu-Mures, 540000, Romania
3 Griffith University School of Dentistry and Oral Health, Gold Coast Campus, Griffith University, Griffith, QLD 4222, Australia
4 Department of Pathology, Gold Coast University Hospital, Nerang Street, Southport, QLD 4215, Australia
5 Manchester Metropolitan University, Inst for Biomedical Research, John Dalton Building, Oxford Road, Manchester, M1 5GD, UK
6 Griffith University School of Medicine, Gold Coast Campus, Griffith University, Griffith, QLD 4222, Australia
7 Department of Anatomy, University of Medicine and Pharmacy Targu Mures, Gh.Marinescu 38, Targu-Mures, 540000, Romania
Citation and License
Diagnostic Pathology 2012, 7:78 doi:10.1186/1746-1596-7-78Published: 6 July 2012
Bisphosphonates are recommended in the treatment of osteoporosis and some cancers, in which case they prevent the appearance of bone metastasis. The patients taking bisphosphonates are at increased risk of developing bisphosphonate-related osteonecrosis of jaw (BRONJ) which is characterised by the presence of an un-healing wound after dental surgery. BRONJ might represent an anti-angiogenic side effect. However, the real number of patients with BRONJ might be higher than currently recorded. Considering the differential diagnosis which includes various primary and secondary cancers, a correct histopathological diagnosis is very important. The morphological criteria for diagnosis of BRONJ are highlighted in this material.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1813972972323288